[go: up one dir, main page]

SV2016005290A - Derivados de nucleósido 4'- sustituidos como inhibidores de la transcriptasa reversa de vih - Google Patents

Derivados de nucleósido 4'- sustituidos como inhibidores de la transcriptasa reversa de vih

Info

Publication number
SV2016005290A
SV2016005290A SV2016005290A SV2016005290A SV2016005290A SV 2016005290 A SV2016005290 A SV 2016005290A SV 2016005290 A SV2016005290 A SV 2016005290A SV 2016005290 A SV2016005290 A SV 2016005290A SV 2016005290 A SV2016005290 A SV 2016005290A
Authority
SV
El Salvador
Prior art keywords
inhibitors
hiv reverse
nucleoside derivatives
reverse transcript
derivatives replaced
Prior art date
Application number
SV2016005290A
Other languages
English (en)
Inventor
David B Olsen
Zhibo Zhang
Jianmin Fu
Bing-Yu Tang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52824598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2016005290(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of SV2016005290A publication Critical patent/SV2016005290A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A DERIVADOS DE NUCLEÓSIDOS 4' SUSTITUIDOS DE FÓRMULA: (VER FORMULA); Y SU USO EN LA INHIBICIÓN DE LA TRANSCRIPTASA REVERSA DE VIH, LA PROFILAXIS DE LA INFECCIÓN POR VIH, EL TRATAMIENTO DE LA INFECCIÓN POR EL VIH, Y LA PROFILAXIS, TRATAMIENTO, Y RETRASO EN LA APARICIÓN O PROGRESIÓN DE SIDA Y/O ARC
SV2016005290A 2014-03-28 2016-09-28 Derivados de nucleósido 4'- sustituidos como inhibidores de la transcriptasa reversa de vih SV2016005290A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2014/074294 WO2015143712A1 (en) 2014-03-28 2014-03-28 4'-substituted nucleoside reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
SV2016005290A true SV2016005290A (es) 2018-05-03

Family

ID=52824598

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2016005290A SV2016005290A (es) 2014-03-28 2016-09-28 Derivados de nucleósido 4'- sustituidos como inhibidores de la transcriptasa reversa de vih

Country Status (42)

Country Link
US (2) US9777035B2 (es)
EP (1) EP3122752B1 (es)
JP (1) JP6182680B2 (es)
KR (1) KR101961009B1 (es)
CN (1) CN106795199B (es)
AP (1) AP2016009482A0 (es)
AR (2) AR099788A1 (es)
AU (2) AU2015236018B2 (es)
CA (1) CA2943792C (es)
CL (1) CL2016002414A1 (es)
CR (1) CR20160451A (es)
CY (1) CY1124829T1 (es)
DK (1) DK3122752T3 (es)
DO (1) DOP2016000265A (es)
EA (1) EA031476B1 (es)
EC (1) ECSP16085206A (es)
ES (1) ES2894228T3 (es)
GE (2) GEP20197009B (es)
GT (1) GT201600201A (es)
HR (1) HRP20211622T1 (es)
HU (1) HUE056913T2 (es)
IL (1) IL247923B (es)
JO (1) JO3636B1 (es)
LT (1) LT3122752T (es)
MA (1) MA39809B1 (es)
MD (1) MD4812C1 (es)
MX (1) MX367058B (es)
MY (1) MY194635A (es)
NI (1) NI201600145A (es)
NZ (1) NZ724343A (es)
PE (1) PE20170197A1 (es)
PH (1) PH12016501897B1 (es)
PL (1) PL3122752T3 (es)
PT (1) PT3122752T (es)
RS (1) RS62418B1 (es)
SG (1) SG11201608031PA (es)
SI (1) SI3122752T1 (es)
SV (1) SV2016005290A (es)
TW (1) TWI660967B (es)
UA (1) UA120758C2 (es)
WO (2) WO2015143712A1 (es)
ZA (1) ZA201606413B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA025252B1 (ru) 2010-07-22 2016-12-30 Гайлид Сайэнсиз, Инк. Способы и соединения для лечения вирусных инфекций paramyxoviridae
MA41213A (fr) * 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
WO2017027645A1 (en) 2015-08-13 2017-02-16 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
AU2016328303B2 (en) 2015-09-23 2019-05-02 Merck Sharp & Dohme (Uk) Limited 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
CR20190168A (es) 2016-10-04 2019-05-17 Merck Sharp & Dohme Compuestos de benzo[b]tiofeno como agonistas de sting
JP7125714B2 (ja) * 2016-12-13 2022-08-25 ヤマサ醤油株式会社 抗ウイルス活性を有する２’－デオキシ－７－デアザプリンヌクレオシド誘導体
EP3621624B1 (en) 2017-05-12 2023-08-30 Merck Sharp & Dohme LLC Cyclic di-nucleotide compounds as sting agonists
WO2019027857A1 (en) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO [B] THIOPHENIC AGONISTS FOR THE TREATMENT OF CANCER
EP3661498A4 (en) 2017-08-04 2021-04-21 Merck Sharp & Dohme Corp. BENZO [B] THIOPHEN STING ANTAGONISTS FOR CANCER TREATMENT
MX2020002925A (es) * 2017-09-18 2020-10-05 Janssen Biopharma Inc Nucleósidos sustituidos, nucleótidos y análogos de estos.
US11685761B2 (en) 2017-12-20 2023-06-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
WO2019133712A1 (en) * 2017-12-27 2019-07-04 Schinazi Raymond F Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents
WO2019171285A1 (en) * 2018-03-07 2019-09-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
EP3774765A4 (en) 2018-04-03 2021-12-29 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
US10793557B2 (en) 2018-04-03 2020-10-06 Merck Sharp & Dohme Corp. Sting agonist compounds
BR112021000202B1 (pt) * 2018-07-09 2023-03-28 Merck Sharp & Dohme Llc Métodos para síntese enzimática de nucleosídeo 4'-etinila 2-desóxi e compostos
WO2020031131A1 (en) * 2018-08-09 2020-02-13 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
AU2020211600A1 (en) 2019-01-25 2021-07-22 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
MA55200A (fr) 2019-03-06 2022-01-12 Glaxosmithkline Ip No 2 Ltd Composés utiles dans la thérapie du vih
CN110054654B (zh) * 2019-05-27 2022-12-27 武汉百科药物开发有限公司 一种地西他滨中间体α-取代脱氧核糖的合成方法
AU2020320876B2 (en) 2019-07-27 2025-09-25 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
BR112022004424A2 (pt) * 2019-09-11 2022-05-31 Scripps Research Inst Pró-fármacos antivirais e formulações dos mesmos
IL293566A (en) * 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir
CN112321589B (zh) * 2020-02-18 2022-05-03 山东科巢生物制药有限公司 一种抗病毒药物瑞德西韦及其中间体的合成方法
JP7429799B2 (ja) 2020-02-18 2024-02-08 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
EP4121437A1 (en) * 2020-03-20 2023-01-25 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
CN112778310B (zh) * 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN113527303B (zh) * 2020-04-21 2022-06-10 浙江工业大学 一种瑞德西韦母核中间体的制备工艺
CN113637041B (zh) * 2020-05-11 2024-02-27 上海科胜药物研发有限公司 一种核糖核苷的制备方法
KR102911165B1 (ko) 2020-06-24 2026-01-13 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오시드 유사체 및 이의 용도
JP7712352B2 (ja) 2020-08-07 2025-07-23 ギリアード サイエンシーズ， インコーポレイテッド ホスホンアミドヌクレオチド類似体のプロドラッグ及びその薬学的使用
SI4204421T1 (sl) * 2020-08-27 2024-07-31 Gilead Sciences, Inc., Spojine in postopki za zdravljenje virusnih okužb
US20240101589A1 (en) 2020-10-08 2024-03-28 Strom Therapeutics Limited Inhibitors of mettl3
CN112300236A (zh) * 2020-10-21 2021-02-02 佛山科学技术学院 核苷酸混合氨基磷酸酯化合物、其药物组合物及其应用
CA3202049A1 (en) 2021-01-25 2022-07-28 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
WO2022159877A1 (en) 2021-01-25 2022-07-28 Brii Biosciences, Inc. Combination therapy for hiv with adenosine derivative and capsid inhibitors
US11697666B2 (en) 2021-04-16 2023-07-11 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
KR20240049311A (ko) 2021-08-18 2024-04-16 길리애드 사이언시즈, 인코포레이티드 인지질 화합물 및 이의 제조 및 사용 방법
KR20240050362A (ko) 2021-08-20 2024-04-18 시오노기 앤드 컴파니, 리미티드 바이러스 증식 억제 작용을 갖는 뉴클레오사이드 유도체 및 그들의 프로드러그
EP4405357A1 (en) 2021-09-23 2024-07-31 Katholieke Universiteit Leuven KU Leuven Research & Development Ribonucleoside analogues against -sars-cov-2
IL315102A (en) 2022-03-02 2024-10-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
PE20250684A1 (es) 2022-03-15 2025-03-04 Rome Therapeutics Inc Compuestos y metodos para el tratamiento de enfermedades
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
EP4658663A2 (en) 2023-01-30 2025-12-10 Merck Sharp & Dohme LLC Prodrugs of 4'-substituted nucleoside reverse transcriptase inhibitors
CN121358474A (zh) * 2023-04-26 2026-01-16 莱克伍德阿美达克斯股份有限公司 取代的嘧啶酮和氮杂嘧啶酮化合物、其组合物及其用途
AR133187A1 (es) 2023-07-07 2025-09-03 Merck Sharp & Dohme Llc Derivados de tetrahidroquinazolina como agentes citotóxicos selectivos

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
HUT63170A (en) 1990-01-11 1993-07-28 Isis Pharmaceuticals Inc Process and composition for detecting and modifying rna activity and gene expression
CZ126799A3 (cs) 1996-10-16 1999-07-14 Icn Pharmaceuticals Purinové L-nukleosidy a jejich analogy a farmaceutické prostředky, které je obsahují
ATE250622T1 (de) 1999-05-12 2003-10-15 Yamasa Corp 4'-c-ethynyl-pyrimidine nukleoside
US6831069B2 (en) 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
AU2003237249A1 (en) 2002-05-24 2003-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
WO2005003047A1 (en) 2003-07-03 2005-01-13 Philips Intellectual Property & Standards Gmbh Pane which can be heated by means of invisible light
CA2502109C (en) 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
CA2637879A1 (en) 2006-02-14 2007-08-23 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
CN101003550B (zh) * 2006-12-30 2010-05-19 河南省分析测试研究中心 8-卤代腺嘌呤类核苷化合物、合成方法和其药物用途
EP2535345A1 (en) 2007-01-12 2012-12-19 BioCryst Pharmaceuticals, Inc. Anticancer nucleoside analogs
CN100532388C (zh) * 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090318380A1 (en) * 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
EA020659B1 (ru) 2008-04-23 2014-12-30 Джилид Сайэнс, Инк. 1'-замещённые карбануклеозидные аналоги для противовирусной терапии
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
GB0815968D0 (en) 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
JPWO2010027005A1 (ja) 2008-09-05 2012-02-02 壽製薬株式会社 置換アミン誘導体及びこれを有効成分とする医薬組成物
EP2376514A2 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
US8716262B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Nucleoside phosphoramidates
DE102009000180A1 (de) 2009-01-13 2010-07-15 Evonik Degussa Gmbh Verfahren zur Herstellung von mehrschichtig beschichteten Gummipartikeln und mehrschichtig beschichtete Gummipartikel
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
KR20110128947A (ko) 2009-03-20 2011-11-30 앨리오스 바이오파마 인크. 치환된 뉴클레오시드 및 뉴클레오티드 유사체
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
PE20121480A1 (es) 2009-12-17 2012-11-10 Merck Sharp & Dohme Aminopirimidinas como inhibidores de syk
KR20130083389A (ko) 2010-05-28 2013-07-22 바이오크리스트파마슈티컬즈,인코포레이티드 야누스 키나아제 억제제로서 헤테로사이클릭 화합물
EA025252B1 (ru) 2010-07-22 2016-12-30 Гайлид Сайэнсиз, Инк. Способы и соединения для лечения вирусных инфекций paramyxoviridae
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
CN106749272B (zh) * 2012-03-13 2019-08-30 吉利德科学公司 用于抗病毒治疗的2’-取代的卡巴-核苷类似物
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ

Also Published As

Publication number Publication date
WO2015148746A1 (en) 2015-10-01
NI201600145A (es) 2016-10-27
LT3122752T (lt) 2021-11-10
NZ724343A (en) 2020-02-28
MD4812C1 (ro) 2023-01-31
HRP20211622T1 (hr) 2022-03-04
MD20160117A2 (ro) 2017-02-28
GEAP201914307A (en) 2019-04-10
US20150274767A1 (en) 2015-10-01
MA39809A (fr) 2021-04-07
PE20170197A1 (es) 2017-03-22
SG11201608031PA (en) 2016-10-28
ZA201606413B (en) 2018-04-25
PH12016501897A1 (en) 2016-12-19
EP3122752A1 (en) 2017-02-01
CL2016002414A1 (es) 2017-05-05
WO2015143712A1 (en) 2015-10-01
EA031476B1 (ru) 2019-01-31
JP2017512797A (ja) 2017-05-25
MX2016012659A (es) 2016-12-14
MY194635A (en) 2022-12-08
RS62418B1 (sr) 2021-10-29
CA2943792A1 (en) 2015-10-01
CN106795199A (zh) 2017-05-31
DOP2016000265A (es) 2017-04-30
AR099788A1 (es) 2016-08-17
MA39809B1 (fr) 2021-10-29
BR112016022438A2 (pt) 2017-08-15
BR112016022438A8 (pt) 2021-06-29
PH12016501897B1 (en) 2023-08-02
ECSP16085206A (es) 2017-08-31
IL247923A0 (en) 2016-11-30
GT201600201A (es) 2018-12-18
EP3122752B1 (en) 2021-08-25
AU2017225090A1 (en) 2017-09-28
TWI660967B (zh) 2019-06-01
US20180002366A1 (en) 2018-01-04
AU2015236018B2 (en) 2017-09-28
CR20160451A (es) 2016-12-06
AP2016009482A0 (en) 2016-10-31
JP6182680B2 (ja) 2017-08-16
AU2017225090B2 (en) 2018-08-09
SI3122752T1 (sl) 2021-11-30
HUE056913T2 (hu) 2022-03-28
AU2015236018A1 (en) 2016-10-06
MD4812B1 (ro) 2022-06-30
EA201691931A1 (ru) 2017-02-28
AR130699A2 (es) 2025-01-08
MX367058B (es) 2019-08-02
CN106795199B (zh) 2020-01-10
KR20160128437A (ko) 2016-11-07
KR101961009B1 (ko) 2019-03-21
GEP20197009B (en) 2019-08-12
UA120758C2 (uk) 2020-02-10
IL247923B (en) 2021-01-31
PL3122752T3 (pl) 2022-01-03
JO3636B1 (ar) 2020-08-27
CA2943792C (en) 2020-02-25
PT3122752T (pt) 2021-10-20
US9777035B2 (en) 2017-10-03
DK3122752T3 (da) 2021-10-25
ES2894228T3 (es) 2022-02-14
TW201619180A (zh) 2016-06-01
CY1124829T1 (el) 2022-11-25

Similar Documents

Publication Publication Date Title
SV2016005290A (es) Derivados de nucleósido 4'- sustituidos como inhibidores de la transcriptasa reversa de vih
MX2022002579A (es) Compuestos de aminotiazol como inhibidores de c- kit.
MX2022002581A (es) Compuestos de benzimidazol como inhibidores de c-kit.
SV2018005629A (es) Compuestos antivirales de fosfodiamida de ester de beta-aminoacido
CR20150183A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
SI3347352T1 (sl) Terapevtske spojine uporabne za profilaktično ali terapevtsko zdravljenje okužbe z virusom HIV
PH12017500207A1 (en) Indoles for use in influenza virus infection
CR20120503A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
BR112017013858A2 (pt) n4-hidroxicitidina e derivados e usos antivirais relacionados aos mesmos
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
MX2018003212A (es) Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos.
MX2017000312A (es) Derivados de isoindolina para usarse en el tratamiento de una infeccion viral.
GEP20207190B (en) Methods for treatment and prophylaxis of hiv and aids
BR112016022722A2 (pt) pró-fármacos de inibidores da transcriptase reversa de hiv
MX364704B (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.